BiotechTube

Infigratinib

Phase 2Terminated
2 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastric Cancer

Conditions

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

Trial Timeline

Oct 19, 2023 → May 31, 2024

NCT ID
NCT06206278

About Infigratinib

Infigratinib is a phase 2 stage product being developed by LianBio for Gastric Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT06206278. Target conditions include Gastric Cancer, Gastroesophageal Junction Adenocarcinoma.

What happened to similar drugs?

5 of 20 similar drugs in Gastric Cancer were approved

Approved (5) Terminated (3) Active (13)
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅ApatinibJiangsu Hengrui MedicineApproved
✅Esomeprazole SodiumAstraZenecaApproved
✅trastuzumab [Herceptin]RocheApproved
✅Methylnaltrexone only + Codeine only + Methylnaltrexone + codeine + Placebo + placeboPfizerApproved
🔄Trastuzumab + Fluorouracil + Cisplatin + CapecitabineChugai PharmaceuticalPhase 3
🔄Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06206278Phase 2Terminated
NCT05019794Phase 2UNKNOWN

Competing Products

20 competing products in Gastric Cancer

See all competitors
ProductCompanyStageHype Score
pemetrexed + cisplatinEli LillyPhase 1/2
32
InfigratinibLianBioPhase 2
21
Ramucirumab + MEDI4736Eli LillyPhase 1
29
RamucirumabEli LillyPhase 2
35
Trastuzumab + Capecitabine + CisplatinCelltrionPhase 2
31
Trastuzumab + Fluorouracil + Cisplatin + CapecitabineChugai PharmaceuticalPhase 3
40
Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + RilvegostomigDaiichi SankyoPhase 2
42
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
44
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
42
Trastuzumab deruxtecan + BevacizumabDaiichi SankyoPhase 2
42
Trastuzumab deruxtecanDaiichi SankyoPhase 2
35
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
33
DS-8201aDaiichi SankyoPhase 1
29
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Irinotecan + NimotuzumabDaiichi SankyoPhase 3
32
Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + ChemotherapyDaiichi SankyoPhase 3
47
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42